Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODM-201 Maintenance in mCRPC (SAKK 08/16)
NCT02933801Phase 2Terminated
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Mar 2017
- Primary completion
- Jun 2021
- Modality
- Orthosteric Ligands
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing ODM-201 with Placebo (2 arms). Primary endpoint: Radiographic Progression-Free Survival at 12 weeks. Started Mar 2017; status: terminated.
02
Drugs
darolutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02933801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02933801.